School of Medicine
Showing 41-50 of 135 Results
-
Rachel Keranen
Casual - Non-Exempt, Medicine
Current Role at StanfordExecutive and strategic communications for the Department of Medicine.
-
Andreas Kerschbaumer
Postdoctoral Scholar, Immunology and Rheumatology
BioDr. Andreas Kerschbaumer is a postdoctoral scholar in the Division of Immunology and Rheumatology at Stanford University, conducting research in the Robinson and Khatri Labs. His work integrates clinical rheumatology with computational and systems immunology, applying meta-analytic techniques on transcriptomic datasets to uncover mechanisms of autoimmunity and improve therapeutic strategies in rheumatology.
He trained in internal medicine and rheumatology at the Medical University of Vienna, Department of Medicine III, Division of Rheumatology, where he also completed his PhD under Professors Smolen and Aletaha on treatment outcomes in inflammatory arthritis, followed by his habilitation on strategies to optimize the interpretation of clinical trial data in rheumatoid and psoriatic arthritis.
Dr. Kerschbaumer has been actively engaged with the European Alliance of Associations for Rheumatology (EULAR), contributing as Fellow, Methodologist, and Co-Methodologist to multiple international taskforces, including the 2019, 2022, and 2025 rheumatoid arthritis recommendations and the 2019 and 2023 psoriatic arthritis recommendations. He is currently a member of the EULAR Quality of Care Committee and serves as Co-Abstract Chair of the ACR Rheumatoid Arthritis abstract committee. -
Kian Keyashian
Clinical Associate Professor, Medicine - Gastroenterology & Hepatology
BioThe management of inflammatory bowel disease continues to evolve, with the introduction of biologic and small molecule therapies and new goals of treatment, with an emphasis on healing the bowel. My career goal since my graduation from IBD fellowship in 2012 has been to improve the outcomes and quality of life of patients with inflammatory bowel disease. In line with these goals, my research has focused investigating new noninvasive diagnostic test, finding factors early in the disease course that might predict a more aggressive disease course and need for different therapies, and investigating new promising effective medications with less side effects.
-
Ali Raza Khaki, MD
Clinical Assistant Professor, Medicine - Oncology
BioDr. Khaki is a medical oncologist and clinical assistant professor at Stanford University School of Medicine.
In his clinical practice, he treats patients with all forms of genitourinary cancer, including kidney, bladder, prostate, and testicular. He also regularly attends on the inpatient oncology service at Stanford Hospital.
With each patient, he is devoted to providing exceptional, humanistic care and has been recognized throughout his career for his humanism. As a medical student, he was named to the national Gold Humanism Honor Society and he received the Reza Gandjei Humanism Award as a medical resident at UCSF.
His research interests include novel therapies for genitourinary cancers, with a focus on urothelial cancer outcomes. He is the site principal investigator for multiple clinical trails investigating new therapies for genitourinary cancers.
Dr. Khaki is also active working clinically in inpatient oncology and is a Unit Based Medical Director for G1, an oncology hospital unit and is the Director of Inpatient Oncology. In this role, he oversees the inpatient oncology teams, works closely with the cancer center to develop new transitions of care pathways from inpatient to outpatient and has co-led an inpatient oncology research group to study quality improvement, care delivery and end-of-life care for patients with cancer.
Dr. Khaki has earned honors and recognition from the American Association for Cancer Research, American Society of Clinical Oncology, Bladder Cancer Advocacy Network, Conquer Cancer Foundation, and other organizations.
He has authored numerous articles on topics such as immunotherapy for urothelial cancer, management of cancer patients with COVID-19, and utilization of end-of-life care by cancer patients. In addition, he is an editor for HemOnc.org and theMednet, a physician-only online community where members share clinical questions and answers.
